Research progress in the prevention and treatment of radiation-induced heart disease

Ye Sun, Chenyi Zheng, Lian Li, Shenglin Zhang, Jiajuan Guo, Jungang LvFrontiers in Pharmacology 2025 · DOI

Abstract

Radiotherapy (RT) is a cornerstone treatment for thoracic malignancies, but is associated with an increased risk of radiation-induced heart disease (RIHD), a major cause of long-term morbidity and mortality in cancer survivors. Ionizing radiation directly damages cellular components (proteins, lipids, and DNA), disrupts the mitochondrial electron transport chain, and activates enzymes such as NADPH oxidases, this leads to excessive production and accumulation of reactive oxygen species (ROS). Oxidative stress triggers the pro-inflammatory NF-κB pathway, pro-oxidative MAPK branch of IGF-1 signaling, and the pro-fibrotic TGF-β1 pathway. These cascades promote chronic inflammation, endothelial dysfunction, and microvascular damage, leading to myocardial fibrosis and dysfunction. Antioxidant and anti-inflammatory therapies represent a promising approach for the clinical management of RIHD. Preclinical evidence has suggested that statins, angiotensin-converting enzyme inhibitors (ACEIs), and natural antioxidants such as sodium Tanshinone IIA sulfonate mitigate RIHD by scavenging ROS, reducing inflammation, and inhibiting fibrosis. However, further clinical validation of these drugs is required for RIHD. This review highlights the current research status of the known pathophysiological mechanisms of RIHD, and the various treatment strategies used for its prevention and treatment.

Introduction: The Challenge of Collateral Damage

Radiotherapy (RT) remains a cornerstone in the treatment of thoracic malignancies, including breast, lung, and esophageal cancers. However, the heart often receives "collateral" ionizing radiation, leading to radiation-induced heart disease (RIHD). RIHD encompasses a spectrum of conditions—such as cardiomyopathy, coronary artery disease, arrhythmias, and valvular issues—that can manifest decades after treatment.

A critical quantitative insight in cardio-oncology is the "7.4% Rule": for every 1 Gy increase in mean heart dose (MHD), the long-term risk of major adverse cardiac events (MACE) increases by approximately 7.4%. Despite modern, high-precision techniques like Intensity-Modulated Radiotherapy (IMRT) and Deep Inspiration Breath-Hold (DIBH)—which can reduce MHD by 30%–50%—the risk to adjacent cardiac tissue cannot be entirely eliminated.

Molecular Mechanisms: The ROS Central Hub

The pathophysiology of RIHD is driven by a molecular "domino effect" initiated by Reactive Oxygen Species (ROS). Radiation disrupts the mitochondrial electron transport chain and activates enzymes like NADPH oxidases, creating a state of chronic oxidative stress that persists long after treatment.

Graphical abstract illustrating the molecular pathways of radiation-induced heart disease, including ROS production, inflammation, and fibrotic signaling leading to clinical cardiac conditions.

This oxidative stress acts as a "master switch" for three primary signaling axes:

  1. Inflammation: Mediated by the NF-κB pathway, leading to chronic inflammatory responses.
  2. Vasomotor Dysfunction: Driven by pro-oxidative MAPK branches of IGF-1 signaling.
  3. Fibrosis: Controlled by the TGF-β1/Smad3 pathway. ROS can induce "epigenetic reprogramming," such as DNA demethylation at the TGF-β1 promoter, keeping fibrotic signals "switched on" for years, eventually leading to permanent myocardial scarring.

Pharmacological Interventions and Clinical Evidence

Current research focuses on repurposing existing drugs and exploring natural compounds to act as pharmacological shields for the heart.

Established Drug Classes

  • Statins: Beyond lipid-lowering, statins exhibit pleiotropic effects, including ROS scavenging. Clinical data from 1,481 breast cancer patients showed that statin therapy was associated with a significant reduction in MACE risk (adjusted Hazard Ratio = 0.34).
  • ACE Inhibitors (ACEIs): These drugs help mitigate RIHD by inhibiting the signaling pathways that lead to heart scarring and improving endothelial function.
  • Metformin: Emerging evidence suggests metformin may prevent RIHD by promoting DNA repair and inhibiting radiation-induced cellular senescence.

Natural Antioxidants

Preclinical models have demonstrated the efficacy of several natural compounds in mitigating damage:

  • Sodium Tanshinone IIA Sulfonate (STS): Shows cardioprotective effects by reducing biomarkers of fibrosis (Col-1).
  • Astragaloside IV (AST): Mitigates inflammation and oxidative damage in animal models.

Current Limitations and Future Directions

Despite promising preclinical results, several "bottlenecks" remain in the clinical management of RIHD:

  • Need for RCTs: Most current evidence stems from animal models or retrospective analyses. Large-scale, prospective randomized controlled trials (RCTs) are essential to establish definitive protocols.
  • Optimal Timing: The ideal "treatment window"—whether to start cardioprotective drugs before, during, or after radiotherapy—remains undefined.
  • Biomarker Sensitivity: While high-sensitivity cardiac troponin (hs-cTnI/T) and BNP are useful, more robust biomarkers are needed to detect subclinical damage before it becomes irreversible.
  • Balancing Efficacy: A critical concern is ensuring that antioxidant therapies do not interfere with the tumor-killing efficacy of radiation. Future research must navigate this "double-edged sword" to protect the heart without compromising cancer control.

Summary updated

Abstract

Radiotherapy (RT) is a cornerstone treatment for thoracic malignancies, but is associated with an increased risk of radiation-induced heart disease (RIHD), a major cause of long-term morbidity and mortality in cancer survivors. Ionizing radiation directly damages cellular components (proteins, lipids, and DNA), disrupts the mitochondrial electron transport chain, and activates enzymes such as NADPH oxidases, this leads to excessive production and accumulation of reactive oxygen species (ROS). Oxidative stress triggers the pro-inflammatory NF-κB pathway, pro-oxidative MAPK branch of IGF-1 signaling, and the pro-fibrotic TGF-β1 pathway. These cascades promote chronic inflammation, endothelial dysfunction, and microvascular damage, leading to myocardial fibrosis and dysfunction. Antioxidant and anti-inflammatory therapies represent a promising approach for the clinical management of RIHD. Preclinical evidence has suggested that statins, angiotensin-converting enzyme inhibitors (ACEIs), and natural antioxidants such as sodium Tanshinone IIA sulfonate mitigate RIHD by scavenging ROS, reducing inflammation, and inhibiting fibrosis. However, further clinical validation of these drugs is required for RIHD. This review highlights the current research status of the known pathophysiological mechanisms of RIHD, and the various treatment strategies used for its prevention and treatment.
BibTeX
@inproceedings{sun2025research,
  author = {Ye Sun and Chenyi Zheng and Lian Li and Shenglin Zhang and Jiajuan Guo and Jungang Lv},
  title = {{Research progress in the prevention and treatment of radiation-induced heart disease}},
  booktitle = {Frontiers in Pharmacology},
  year = {2025},
  doi = {10.3389/fphar.2025.1745302},
}
Figure